Comparison of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation

Journal of Anesthesia

Volumn 28, Issue 4, 2014, Pages 587-592

  Harayama, Nobuya ^a   Nihei, Shun Ichi ^a   Nagata, Keiji ^a   Isa, Yasuki ^a   Goto, Kei ^a   Aibara, Keiji ^a   Kamochi, Masayuki ^a   Sata, Takeyoshi ^b  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Amiodarone; Cardiopulmonary resuscitation; Nifekalant; Out of hospital cardiopulmonary arrest; Ventricular fibrillation

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; NIFEKALANT; PYRIMIDINONE DERIVATIVE;

AGED; CARDIOVERSION; COMPARATIVE STUDY; COMPLICATION; DOSE RESPONSE; FEMALE; HEART VENTRICLE FIBRILLATION; HUMAN; MALE; MIDDLE AGED; OUT-OF-HOSPITAL CARDIAC ARREST; PROCEDURES; PROSPECTIVE STUDY; RESUSCITATION; RETROSPECTIVE STUDY;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; CARDIOPULMONARY RESUSCITATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; MALE; MIDDLE AGED; OUT-OF-HOSPITAL CARDIAC ARREST; PROSPECTIVE STUDIES; PYRIMIDINONES; RETROSPECTIVE STUDIES; VENTRICULAR FIBRILLATION;

EID: 84905923838     PISSN: 09138668     EISSN: 14388359     Source Type: Journal    
DOI: 10.1007/s00540-013-1775-5     Document Type: Article

References (31)

1. Valenzuela TD, Roe DJ, Nichol G, Clark LL, Spaite DW, Hardman RG. Outcomes of rapid defibrillation by security officers after cardiac arrest in casinos. N Engl J Med. 2000;343:1206-9.
2. Weisfeldt ML, Sitlani CM, Ornato JP, Rea T, Aufderheide TP, Davis D, Dreyer J, Hess EP, Jui J, Maloney J, Sopko G, Powell J, Nichol G, Morrison LJ, for the ROC Investigators. Survival after application of automatic external defibrillators before arrival of the emergency medical system: evaluation in the resuscitation outcomes consortium population of 21 million. J Am Coll Cardiol. 2010;55:1713-20.
3. Kitamura T, Iwami T, Kawamura T, Nagao K, Tanaka H, Hiraide A. Nationwide public-access defibrillation in Japan. N Engl J Med. 2010;362:994-1004.
4. Kudenchuk PJ, Cobb LA, Copass MK, Cummins RO, Doherty AM, Fahrenbruch CE, Hallstrom AP, Murray WA, Olsufka M, Walsh T. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 1999;341:871-8. (Pubitemid 29427049)
5. Deakin CD, Nolan JP, Soar J, Sunde K, Koster RW, Smith GB, Perkins GD. European Resuscitation Council Guidelines for Resuscitation 2010, Section 4. Adult advanced life support. Resuscitation. 2010;81:1305-52.
6. Neumar RW, Otto CW, Link MS, Kronick SL, Shuster M, Callaway CW, Kudenchuk PJ, Ornato JP, McNally B, Silvers SM, Passman RS, White RD, Hess EP, Tang W, Davis D, Sinz E, Morrison LJ. Part 8: adult advanced cardiovascular life support. 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122:S729-67.
7. Katoh T, Mitamura H, Matsuda N, Takano T, Ogawa S, Kasanuki H. Emergency treatment with nifekalant, a novel class III antiarrhythmic agent, for life-threatening refractory ventricular tachyarrhythmias: post-marketing special investigation. Circ J. 2005;69:1237-43. (Pubitemid 41382946)
8. The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation. 1991;84:1831-51.
9. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res. 1997;35:13-29. (Pubitemid 27374736)
10. Nakaya H, Tohse N, Takeda Y, Kanno M. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Br J Pharmacol. 1993;109:157-63. (Pubitemid 23113815)
11. Sen L, Cui G, Sakaguchi Y, Singh BN. Electrophysiological effects of MS-551, a new class III agent: comparison with dlsotalol in dogs. J Pharmacol Exp Ther. 1998;285:687-94. (Pubitemid 28237449)
12. Kondoh K, Hashimoto H, Nishiyama H, Umemura K, Ozaki T, Uematsu T, Nakashima M. Effects of MS-551, a new class III antiarrhythmic drug, on programmed stimulation-induced ventricular arrhythmias, electrophysiology, and hemodynamics in a canine myocardial infarction model. J Cardiovasc Pharmacol. 1994;23:674-80. (Pubitemid 24100157)
13. Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 2002;346:884-90. (Pubitemid 34984636)
14. Tahara Y, Kimura K, Kosuge M, Ebina T, Sumita S, Hibi K, Toyama H, Kosuge T, Moriwaki Y, Suzuki N, Sugiyama M, Umemura S. Comparison of nifekalant and lidocaine for the treatment of shock-refractory ventricular fibrillation. Circ J. 2006;70:442-6.
15. Yusu S, Ikeda T, Mera H, Miyakoshi M, Miwa Y, Abe A, Tsukada T, Ishiguro H, Shimizu H, Yoshino H. Effects of intravenous nifekalant as a lifesaving drug for severe ventricular tachyarrhythmias complicating acute coronary syndrome. Circ J. 2009;73:2021-8.
16. Shiga T, Tanaka K, Kato R, Amino M, Matsudo Y, Honda T, Sagara K, Takahashi A, Katoh T, Urashima M, Ogawa S, Takano T, Kasanuki H, for the Refractory VT/VF, Prospective Evaluation to Differentiate Lidocaine Efficacy from Nifekalant (RELIEF) Study Investigators. Nifekalant versus lidocaine for in-hospital shock-resistant ventricular fibrillation or tachycardia. Resuscitation. 2010;81:47-52.
17. (2005) International consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Part 1: Introduction. Resuscitation. 2005;67:181-186.
18. Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet. 1975;1:480-4.
19. Komatsu T, Kinoshita K, Sakurai A, Moriya T, Yamaguchi J, Sugita A, Kogawa R, Tanjoh K. Shorter time until return of spontaneous circulation is the only independent factor for a good neurological outcome in patients with postcardiac arrest syndrome. Emerg Med J. 2013 (in press).
20. Hayakawa K, Tasaki O, Hamasaki T, Sakai T, Shiozaki T, Nakagawa Y, Ogura H, Kuwagata Y, Kajino K, Iwami T, Nishiuchi T, Hayashi Y, Hiraide A, Sugimoto H, Shimazu T. Prognostic indicators and outcome prediction model for patients with return of spontaneous circulation from cardiopulmonary arrest: the Utstein Osaka project. Resuscitation. 2011;82:874-80.
21. Amino M, Yoshioka K, Opthof T, Morita S, Uemura S, Tamura K, Fukushima T, Higami S, Otsuka H, Akieda K, Shima M, Fujibayashi D, Hashida T, Inokuchi S, Kodama I, Tanabe T. Comparative study of nifekalant versus amiodarone for shock-resistant ventricular fibrillation in out-of-hospital cardiopulmonary arrest patients. J Cardiovasc Pharmacol. 2010;55:391-8.
22. Ji XF, Li CS, Wang S, Yang L, Cong LH. Comparison of the efficacy of nifekalant and amiodarone in a porcine model of cardiac arrest. Resuscitation. 2010;81:1031-6.
23. Nolan JP, Hazinski MF, Billi JE, Boettiger BW, Bossaert L, de Caen AR, Deakin CD, Drajer S, Eigel B, Hickey RW, Jacobs I, Kleinman ME, Kloeck W, Koster RW, Lim SH, Mancini ME, Montgomery WH, Morley PT, Morrison LJ, Nadkarni VM, O'Connor RE, Okada K, Perlman JM, Sayre MR, Shuster M, Soar J, Sunde K, Travers AH, Wyllie J, Zideman D. Part 1: Executive summary. 2010 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Resuscitation. 2010;81(suppl 1):e1-25.
24. Desai AD, Chun S, Sung RJ. The role of intravenous amiodarone in the management of cardiac arrhythmias. Ann Intern Med. 1997;127:294-303. (Pubitemid 27352051)
25. Yasuda S, Sawano H, Hazui H, Ukai I, Yokoyama H, Ohashi J, Sase K, Kada A, Nonogi H, on behalf of the J-PULSE Investigators. Report from J-PULSE multicenter registry of patients with shock-resistant out-of-hospital cardiac arrest treated with nifekalant hydrochloride. Circ J. 2010;74:2308-13.
26. Oyabe A, Sano H. Pharmacological and clinical profile of nifekalant (shinbit injection), a class III antiarrhythmic drug (in Japanese, English abstract). Nihon Yakurigaku Zasshi (Folia Pharmacol Jpn). 2002;119:103-9. (Pubitemid 34145545)
27. Shiga T, Tanaka T, Irie S, Hagiwara N, Kasanuki H. Pharmacokinetics of intravenous amiodarone and its electrocardiographic effects on healthy Japanese subjects. Heart Vessels. 2011;26:274-81.
28. Murakawa Y, Yamashita T, Kanese Y, Omata M. Can a class III antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation? J Am Coll Cardiol. 1997;29:688-92. (Pubitemid 27116115)
29. Huang J, Skinner JL, Rogers JM, Smith WM, Holman WL, Ideker RE. The effects of acute and chronic amiodarone on activation patterns and defibrillation threshold during ventricular fibrillation in dogs. J Am Coll Cardiol. 2002;40:375-83. (Pubitemid 34756302)
30. Tsagalou EP, Anastasiou-Nana MI, Charitos CE, Siafakas CX, Drakos SG, Ntalianis A, Terrovitis JV, Mavrikakis EM, Doufas A, Nanas JN. Time course of fibrillation and defibrillation thresholds after an intravenous bolus of amiodarone - an experimental study. Resuscitation. 2004;61:83-9. (Pubitemid 38481636)
31. Nagao K. Nifekalant hydrochloride for patients with cardiac arrest caused by shockable rhythm. Circ J. 2010;74:2285-7.